Basilea Pharmaceutica AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 147
- Market Cap
- $676.7M
- Website
- http://www.basilea.com
Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 12
- Registration Number
- NCT04098692
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
- Conditions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Basilea Pharmaceutica
- Registration Number
- NCT04087876
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
- Conditions
- Interventions
- Drug: Derazantinib 300 mg once daily monotherapy (QD)Drug: Derazantinib 300 mg once daily+ atezolizumab 1200 mgDrug: Derazantinib 200 mg twice daily + atezolizumab 1200 mgDrug: Derazantinib 300 mg once daily monotherapyDrug: Derazantinib 200 mg once daily + atezolizumab 1200 mgDrug: Derazantinib 200 mg twice daily monotherapyDrug: Derazantinib 300 mg once daily + atezolizumab 1200 mg
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 95
- Registration Number
- NCT04045613
- Locations
- ๐บ๐ธ
CTCA Clinical Research Inc., Atlanta, Newnan, Georgia, United States
๐บ๐ธEnglander Institute Weill Cornell Medicine, New York, New York, United States
๐บ๐ธNew York Cancer and Blood Specialists, Port Jefferson Station, New York, United States
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 21
- Registration Number
- NCT03604705
- Locations
- ๐บ๐ธ
Augusta University (Georgia Regents University), Augusta, Georgia, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐ง๐ชUniversite Libre de Bruxelles (ULB) - Hopital Erasme, Brussels, Belgium
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 138
- Registration Number
- NCT03439124
- Locations
- ๐ญ๐บ
Bekes County Central Hospital, Gyula, Hungary
๐ท๐ดSf. Maria" Children's Emergency Clinical Hospital, Iaลi, Romania
๐ญ๐บFejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 20
- Registration Number
- NCT03333005
- Locations
- ๐ฉ๐ช
University of Munich, Grosshadern Campus, Munich, Germany
๐ฉ๐ชJohannes Gutenberg, University of Mainz, Mainz, Germany
๐ฉ๐ชUniversity of Cologne, Center for Integrated Oncology (CIO), Cologne, Germany
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 26
- Registration Number
- NCT03250299
- Locations
- ๐บ๐ธ
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธHillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 148
- Registration Number
- NCT03230318
- Locations
- ๐ง๐ช
Antwerp University Hospital, Edegem, Belgium
๐บ๐ธVanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 390
- Registration Number
- NCT03138733
- Locations
- ๐บ๐ธ
Remington Davis Inc., Columbus, Ohio, United States
๐ฎ๐นGiuliano Isontina University Health Authority, Trieste, Italy
๐ฎ๐ฑThe Baruch Padeh Medical Center, Poriyya 'Illit, Israel
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 679
- Registration Number
- NCT03137173
- Locations
- ๐บ๐ธ
Physician Alliance Research Center, Anaheim, California, United States
๐บ๐ธCentral Valley Research LLC, Fresno, California, United States
๐บ๐ธL&C Professional Medical Research Institute, Miami, Florida, United States